Ankylosing spondylitis and comorbidity: safety of long-term use of nimesulide
https://doi.org/10.14412/1996-7012-2017-4-79-82
Abstract
Ankylosing spondylitis (AS) is a socially significant rheumatic disease that generally starts in young adults and, if untreated, often leads to temporary incapacitation, and by 40 years, and to disability. Despite the relatively young age of patients, the course of AS is accompanied by a number of comorbidities that most commonly include hypertension, dyslipidemia, and involvement of the gastrointestinal tract and kidney. The main group of drugs recommended for the treatment of the disease is nonsteroidal anti-inflammatory drugs (NSAIDs) that, when used long, exert analgesic, anti-inflammatory, and even disease-modifying effects on the one hand and can cause adverse reactions on the other. When choosing NSAIDs, one should consider not only the activity of the pathological process, but also the presence of comorbidities in the patient. The paper gives data on the efficacy and safety of nimesulide in AS. The drug has proven its efficacy and safety in various rheumatic diseases over nearly a quarter century of its use in Russia.
About the Author
R. M. Balabanova
V.A. Nasonova Research Institute of Rheumatology, Moscow
Russian Federation
Russian Federation
References
1. Эрдес ШФ, Бадокин ВВ, Бочкова АГ и др. О терминологии спондилоартритов. Научно-практическая ревматология. 2015;53(6):657-60 [Erdes ShF, Badokin VV, Bochkova AG, et al. On the terminology of spondyloarthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(6):657-60 (In Russ.)]. doi: 10.14412/1995-4484-2015-657-660.
2. Doherty TA, Pilcher J, Njegovan N, Sandhu V. A review of ankylosing spondylitis complications and associations. Ann Rheum Dis. 2013;72:A961-A962. doi: 10.1136/ annrheumdis-2013-eular.2886.
3. Подряднова МВ. Влияние клинических проявлений анкилозирующего спондило-артрита и сопутствующих заболеваний на трудоспособность. Автореф. дисс. … канд. мед. наук. Москва; 2015 [Podryadnova MV. Vliyanie klinicheskikh proyavlenii ankiloziruyushchego spondiloartrita i soputshchikh zabolevanii na trudosposobnost'. Avtoref. diss. … kand. med. nauk [Effect of clinical manifestations of ankylosing spondylitis and related diseases on work capacity. Author's abstract. diss. ... Cand. Med. Sci]. Moscow; 2015].
4. Волнухин ЕВ. Клиническая картина анкилозирующего спондилоартрита
5. в реальной практике врача-ревматолога в России. Автореф. дисс. … канд. мед. наук. Москва; 2013 [Volnukhin EV. Klinicheskaya kartina ankiloziruyushchego spondiloartrita v real'noi praktike vracharevmatologa v Rossii. Avtoref. diss. … kand. med. nauk [Clinical picture of ankylosing spondylitis in the real practice of a rheumatologist in Russia. Author's abstract. diss. ... Cand. Med. Sci]. Moscow; 2013].
6. Han C, Robinsov DW, Hackett MV, et al. Cardio-vascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis. J Rheumatol. 2006;33(11):2167-72.
7. Bumander A, Petersson IF, Bergman S, Englund M. Population-based elimate of common comorbidities and cardio-vascular disease in ankylosing spondylitis. Arthritis Care Res. 2011;63(4):550-6. doi: 10.1002/ acr.20408.
8. Papadakis JA, Sidiropoulos PI, Karvounaris SA, et al. High prevalence of metabolic syndrome and cardio-vascular risk factors in men with ankylosing spondylitis on anti-TNFa treatment: correlation with disease activity. Clin Exper Rheumatol. 2009; 27(2):292-8.
9. Jiunn-Horng Kang, Yi-Hua Chen, Herng-Ching Lin. Comordidity profils among patients with ankylosing spondylitis: a nationwide population-based study. Ann Rheum Dis. 2010;69(6):1165-8. doi: 10.1136/ard.2009. 116178.
10. Dougados M, Gueguen A, Nakache J, et al. Ankylosing spondylitis: what is the optium duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflamatory drug trial. Rheumatology (Oxford). 1999;38(3):235-44.
11. Song IH, Poddubnyy DA, Rudwaleit M, Sieper J, et al. Benefits and risk of ankylosing spondylitis treatment with nonsteroid antyinflamatory drugs. Arthritis Rheum. 2008;58(4): 929-38. doi: 10.1002/art.23275.
12. Ofman JJ, Maclean C, Straus WL, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal anti-inflammatory drugs. J Rheumatol. 2002; 29(4):804-12.
13. Ben Taarit C, Ajlani H, Ben Moussa F, et al. Renal involvement in ankylosing spondylitis: concerning 210 cases. Rev Med Intern. 2005;26(12):966-9. doi: 10.1016/j. revmed.2005.07.017.
14. Lange U, Stapfer G, Ditting T, et al. Pathologic alterations of the heart and the kidney in patients with ankylosing spondylitis. Eur J Med Res. 2007;12(12):573-81.
15. Strobel ES, Fritschka E. Renal diseases in ankylosing spondylitis: review of the literature illustrated by cfse reports. Clin Rheumatol. 1998;17(6):524-30. doi:10.1007/BF01451293.
16. Гайдукова ИЗ, Ребров АП, Полянская ОЛ и др. Длительное применение нимесулида в реальной клинической практике: вопросы безопасности. РMЖ. 2013;(9):433-7 [Gaidukova IZ, Rebrov AP, Polyanskaya OL, et al. Long-term use of nimesulide in real clinical practice: safety issues. RMZh. 2013;(9):433-7 (In Russ.)].
17. Braun J, Pincus T. Mortality, cours of disease and prognosis of patients with anky-losing spondylitis. Clin Exp Rheumatol. 2002;20 Suppl 28:S16-22.
18. Zochling J, Braun J. Mortality in ankylosing spondylitis. Clin Exper Rheum. 2008;26 Suppl 51:S80-4.
19. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the managementof ankylosing spondylitis. Ann Rheum Dis. 2006; 65(4):442-52. doi: 10.1136/ard.2005.041137.
20. Wanders A, van der Heijde D, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52:1756-65. doi: 10.1002/art.21054
21. Kroon F, Landewe R, Dougados M, et al. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis. 2012,71:1623-9. doi: 10.1136/ annrheumdis-2012-201370.
22. Poddubnyy D, Rudwaleit M, Haibel H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis. 2012,71:1616-22. doi: 10.1136/annrheumdis-2011-201252.
23. Rainsford KD. Members of the Consensus Report Group on Nimesulide. Nimesulide – a multifactorial approach to inflamation and pain: scientific and clinical consensus. Curr Med Res Opin. 2006;22(6): 1161-70. doi: 10.1185/030079906X104849.
24. Насонов ЕЛ. Эффективность и переносимость нестероидного противовоспалительного препарата Нимесулид: новые данные. РМЖ. 2001;(15):636 [Nasonov EL. Effectiveness and tolerability of non-steroidal anti-inflammatory drug Nimesulide: new data. RMZh. 2001;(15):636 (In Russ.)].
25. Rainsford KD. Nimesulide: overview of properties and applications. Drugs Today. 2001; 37 Suppl B:3-7.
26. Tassorelli C, Greco R, Sandrini G, et al. Central components of the analgesic/ antihyheralgesic effects of nimesulide: studies in animal models of pain and hyperalgesia. Drugs. 2003;63 Suppl 1:9-22. doi: 10.2165/ 00003495-200363001-00003.
27. Кресс Х, Каратеев АЕ, Кукушкин МЛ. Эффективный контроль боли: научно обоснованные терапевтические подходы. РМЖ. 2016;(12):757-64 [Kress Kh, Karateev AE, Kukushkin ML. Effective pain management: evidence-based therapeutic approaches. RMZh. 2016;(12):757-64
28. (In Russ.)].
29. Zingler G, Hermann B, Fischer T, et al. Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risk. Expert Rev Clin Pharmacol. 2016 Sep 8;9(11):1-14. doi: 10.1080/17512433.2016.1230495.
30. Arfe A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal anti- inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28;354:i4857. doi: 10.1136/bmj.i4857.
31. Балабанова РМ, Подряднова МВ. Выбор нестероидного противовоспалительного препарата при анкилозирующем спондилите. Современная ревматология. 2014;8(4):86-9 [Balabanova RM, Podryadnova MV. Choice of a nonsteroidal anti-inflammatory drug in ankylosing spondylitis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2014;(4): 86-9 (In Russ.)]. doi: 10.14412/2074-2711-2014-4-86-89.
32. Каратеев АЕ. Российский опыт применения нимесулида: обзор клинических испытаний. Consilium mеdicum. 2011;13(9):89-95 [Karateev AE. Russian experience of nimesulide: review of clinical trials. Consilium Medicum. 2011;13(9):89-95 (In Russ.)].
33. Castellsague J, Pisa F, Rosolen V, et al. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other NSAIDs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf. 2013;22(4): 365-75. doi: 10.1002/pds.3385.
34. Donati M, Conforti A, Lenti MC, et al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. Br J Clin Pharmacol. 2016;82(1):238-48. doi: 10.1111/bcp.12938.
35. Шварцман ГИ, Каратеев АЕ. Фармакотерапия хронической боли в спине: есть ли перспективы? Современная ревматология. 2017;11(3):112-20 [Shvartsman GI, Karateev AE. Pharmacotherapy of chronic back pain: Are there prospects? Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2017;11(3):112-20 (In Russ.)]. doi: 10/14412/1996-7012-2017-3-112-120.
Review
For citations:
Balabanova RM. Ankylosing spondylitis and comorbidity: safety of long-term use of nimesulide. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2017;11(4):79-82. (In Russ.) https://doi.org/10.14412/1996-7012-2017-4-79-82
Views:
1016
Email this article 